Details

Autor(en) / Beteiligte

• Akkina, Ramesh
• Allam, Atef
• Balazs, Alejandro B
• Blankson, Joel N
• Burnett, John C
• Casares, Sofia
• Garcia, J Victor
• Hasenkrug, Kim J
• Kashanchi, Fatah
• Kitchen, Scott G
• Klein, Florian
• Kumar, Priti
• Luster, Andrew D
• Poluektova, Larisa Y
• Rao, Mangala
• Sanders-Beer, Brigitte E
• Shultz, Leonard D
• Zack, Jerome A

Titel

Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary

Ist Teil von

• AIDS research and human retroviruses, 2016-02, Vol.32 (2), p.109-119

Ort / Verlag

United States

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• The number of humanized mouse models for the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) and other infectious diseases has expanded rapidly over the past 8 years. Highly immunodeficient mouse strains, such as NOD/SCID/gamma chain(null) (NSG, NOG), support better human hematopoietic cell engraftment. Another improvement is the derivation of highly immunodeficient mice, transgenic with human leukocyte antigens (HLAs) and cytokines that supported development of HLA-restricted human T cells and heightened human myeloid cell engraftment. Humanized mice are also used to study the HIV reservoir using new imaging techniques. Despite these advances, there are still limitations in HIV immune responses and deficits in lymphoid structures in these models in addition to xenogeneic graft-versus-host responses. To understand and disseminate the improvements and limitations of humanized mouse models to the scientific community, the NIH sponsored and convened a meeting on April 15, 2015 to discuss the state of knowledge concerning these questions and best practices for selecting a humanized mouse model for a particular scientific investigation. This report summarizes the findings of the NIH meeting.